Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG
Sponsors
Fondation Franc.Cancerologie Digestive, Grupo Espanol De Tumores Neuroendocrinos, Grupo Espanol Multidisciplinar En Cancer Digestivo, Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA
Conditions
Advanced neuroendocrine carcinomas (NECs) of the digestive system or unknown primary origin.Colorectal cancer and metastatic disease limited to the liver with bad prognosis.Localised Colon Cancer (stage II-III)colorectal cancer
Phase 2
Randomized and multicentre Phase II study of FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab) alone or in combination with hepatic chemoembolization (Lifepearls-Irinotecan) in patients with colorectal cancer and metastatic disease limited to the liver with bad prognosis.
Active, not recruitingCTIS2024-517782-16-00
Start: 2024-10-10Target: 45Updated: 2025-12-09
Phase II randomized trial to assess the effect of intensive vs standard adjuvant chemotherapy in localised colon cancer with circulating tumor DNA
Not yet recruitingCTIS2024-518131-11-02
Target: 124Updated: 2025-01-24
ENGIC - 01 COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) in first-line treatment of patients non-eligible for a doublet/triplet chemotherapy with advanced unresectable KRAS G12C mutated colorectal adenocarcinoma
RecruitingCTIS2024-514030-20-00
Start: 2025-08-29Target: 37Updated: 2026-01-13
Phase II Study Of Tarlatamab Alone Or In Combination With Chemotherapy In Advanced Neuroendocrine Carcinomas Of The Digestive System Or Unknown Primary Origin
RecruitingCTIS2024-514327-42-00
Start: 2025-12-18Target: 87Updated: 2025-09-12